Literature DB >> 16328587

Heart disease, schizophrenia, and affective psychoses: epidemiology of risk in primary care.

Suzanne McDermott1, Robert Moran, Tan Platt, Terri Isaac, Hope Wood, Srikanth Dasari.   

Abstract

A retrospective cohort design was used to study risk factors and cardiovascular end points among adults, with and without psychoses, receiving primary care. Earlier onset of risk factors and heart disease was noted among individuals with schizophrenia compared to those with affective psychoses and no disabilities. Patients with schizophrenia had increased relative risk for obesity, congestive heart failure, dementia, depression and death, while patients with affective psychoses had increased risk for dementia and diabetes.

Entities:  

Mesh:

Year:  2005        PMID: 16328587     DOI: 10.1007/s10597-005-6431-6

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  10 in total

Review 1.  Detection and management of comorbidity in patients with schizophrenia.

Authors:  Alan I Green; Carla M Canuso; Mark J Brenner; Joanne D Wojcik
Journal:  Psychiatr Clin North Am       Date:  2003-03

Review 2.  Understanding the new and evolving profile of adverse drug effects in schizophrenia.

Authors:  Donna A Wirshing; Joseph M Pierre; Stephen M Erhart; Jennifer A Boyd
Journal:  Psychiatr Clin North Am       Date:  2003-03

Review 3.  Medical comorbidity in schizophrenia.

Authors:  D V Jeste; J A Gladsjo; L A Lindamer; J P Lacro
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

4.  The unhealthy lifestyle of people with schizophrenia.

Authors:  S Brown; J Birtwistle; L Roe; C Thompson
Journal:  Psychol Med       Date:  1999-05       Impact factor: 7.723

5.  Excess mortality of schizophrenia. A meta-analysis.

Authors:  S Brown
Journal:  Br J Psychiatry       Date:  1997-12       Impact factor: 9.319

6.  Quality of medical care and excess mortality in older patients with mental disorders.

Authors:  B G Druss; W D Bradford; R A Rosenheck; M J Radford; H M Krumholz
Journal:  Arch Gen Psychiatry       Date:  2001-06

7.  Prevalence and correlates of diabetes in national schizophrenia samples.

Authors:  L Dixon; P Weiden; J Delahanty; R Goldberg; L Postrado; A Lucksted; A Lehman
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

8.  The association of medical comorbidity in schizophrenia with poor physical and mental health.

Authors:  L Dixon; L Postrado; J Delahanty; P J Fischer; A Lehman
Journal:  J Nerv Ment Dis       Date:  1999-08       Impact factor: 2.254

Review 9.  Mortality and medical comorbidity among psychiatric patients: a review.

Authors:  B Felker; J J Yazel; D Short
Journal:  Psychiatr Serv       Date:  1996-12       Impact factor: 3.084

Review 10.  Risk of cardiovascular disease and sudden death in schizophrenia.

Authors:  Michael Davidson
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

  10 in total
  10 in total

1.  An examination of sociodemographic, health, psychological factors, and fruit and vegetable consumption among overweight and obese U.S. veterans.

Authors:  Linda K Ko; Marlyn Allicok; Marci K Campbell; Carmina G Valle; Janelle Armstrong-Brown; Carol Carr; Margaret Dundon; Tammy Anthony
Journal:  Mil Med       Date:  2011-11       Impact factor: 1.437

2.  Immediate and 8-month impact of a medical educational course for general practitioners on knowledge about schizophrenia and its treatment: results of a 3-phase study from Brescia, Italy.

Authors:  Cesare Turrina; Paolo Valsecchi; Alessandra Mosca; Giovanni Parrinello; Erminio Tabaglio; Ovidio Brignoli; Emilio Sacchetti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Quality of care for heart failure among disabled Medicaid recipients with and without severe mental illness.

Authors:  Saul Blecker; Yiyi Zhang; Daniel E Ford; Eliseo Guallar; Susan Dosreis; Donald M Steinwachs; Lisa B Dixon; Gail L Daumit
Journal:  Gen Hosp Psychiatry       Date:  2010-03-16       Impact factor: 3.238

4.  Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.

Authors:  Christoph U Correll; Marco Solmi; Nicola Veronese; Beatrice Bortolato; Stella Rosson; Paolo Santonastaso; Nita Thapa-Chhetri; Michele Fornaro; Davide Gallicchio; Enrico Collantoni; Giorgio Pigato; Angela Favaro; Francesco Monaco; Cristiano Kohler; Davy Vancampfort; Philip B Ward; Fiona Gaughran; André F Carvalho; Brendon Stubbs
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

Review 5.  Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness.

Authors:  Ellen M Janssen; Emma E McGinty; Susan T Azrin; Denise Juliano-Bult; Gail L Daumit
Journal:  Gen Hosp Psychiatry       Date:  2015-03-14       Impact factor: 3.238

Review 6.  The bidirectional relation between psychiatric disorders with selected cardiovascular and endocrinal diseases: an Egyptian perspective.

Authors:  Tarek Okasha; Ash-Shayma Radwan
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

7.  Schizophrenia, cancer and obstetric complications in an evolutionary perspective-an empirically based hypothesis.

Authors:  Antonio Preti; Daniel R Wilson
Journal:  Psychiatry Investig       Date:  2010-12-15       Impact factor: 2.505

8.  Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis.

Authors:  Amanda M Lambert; Helen M Parretti; Emma Pearce; Malcolm J Price; Mark Riley; Ronan Ryan; Natalie Tyldesley-Marshall; Tuba Saygın Avşar; Gemma Matthewman; Alexandra Lee; Khaled Ahmed; Maria Lisa Odland; Christoph U Correll; Marco Solmi; Tom Marshall
Journal:  PLoS Med       Date:  2022-04-19       Impact factor: 11.613

9.  Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.

Authors:  Ken O'Day; Krithika Rajagopalan; Kellie Meyer; Andrei Pikalov; Antony Loebel
Journal:  Clinicoecon Outcomes Res       Date:  2013-09-13

10.  Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.

Authors:  Krithika Rajagopalan; David Trueman; Lydia Crowe; Daniel Squirrell; Antony Loebel
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.